J Lambe1, I Noone2, R Lonergan3, N Tubridy3. 1. Department of Neurology, Saint Vincent's University Hospital, Dublin, Ireland. Jeffrey.lambe@ucdconnect.ie. 2. Department of Stroke, Saint Vincent's University Hospital, Dublin, Ireland. 3. Department of Neurology, Saint Vincent's University Hospital, Dublin, Ireland.
Abstract
BACKGROUND: Fabry disease is an X-linked recessive lysosomal storage disorder that provokes multi-organ morbidity, including early-onset stroke. Worldwide prevalence may be greater than previously estimated, with many experiencing first stroke prior to diagnosis of Fabry disease. AIMS: The aim of this study is to screen a cohort of stroke patients under 70 years of age, evaluating the clinical and economic efficacy of such a broad screening programme for Fabry disease. METHODS: All stroke patients under 70 years of age who were entered into the Saint Vincent's University Hospital stroke database over a 6-month period underwent enzyme analysis and/or genetic testing as appropriate for Fabry disease. Patients' past medical histories were analysed for clinical signs suggestive of Fabry disease. Cost-effectiveness analysis of testing was performed and compared to overall economic impact of young stroke in Ireland. RESULTS: Of 22 patients tested for Fabry disease, no new cases were detected. Few clinical indicators of Fabry disease were identified at the time of testing. CONCLUSION: Broad screening programmes for Fabry disease are highly unlikely to offset the cost of testing. The efficacy of future screening programmes will depend on careful selection of an appropriate patient cohort of young stroke patients with multi-organ morbidity and a positive family history.
BACKGROUND:Fabry disease is an X-linked recessive lysosomal storage disorder that provokes multi-organ morbidity, including early-onset stroke. Worldwide prevalence may be greater than previously estimated, with many experiencing first stroke prior to diagnosis of Fabry disease. AIMS: The aim of this study is to screen a cohort of strokepatients under 70 years of age, evaluating the clinical and economic efficacy of such a broad screening programme for Fabry disease. METHODS: All strokepatients under 70 years of age who were entered into the Saint Vincent's University Hospital stroke database over a 6-month period underwent enzyme analysis and/or genetic testing as appropriate for Fabry disease. Patients' past medical histories were analysed for clinical signs suggestive of Fabry disease. Cost-effectiveness analysis of testing was performed and compared to overall economic impact of young stroke in Ireland. RESULTS: Of 22 patients tested for Fabry disease, no new cases were detected. Few clinical indicators of Fabry disease were identified at the time of testing. CONCLUSION: Broad screening programmes for Fabry disease are highly unlikely to offset the cost of testing. The efficacy of future screening programmes will depend on careful selection of an appropriate patient cohort of young strokepatients with multi-organ morbidity and a positive family history.
Authors: Anna Bersano; Hugh Stephen Markus; Silvana Quaglini; Eloisa Arbustini; Silvia Lanfranconi; Giuseppe Micieli; Giorgio B Boncoraglio; Franco Taroni; Cinzia Gellera; Silvia Baratta; Silvana Penco; Lorena Mosca; Maurizia Grasso; Paola Carrera; Maurizio Ferrari; Cristina Cereda; Gaetano Grieco; Stefania Corti; Dario Ronchi; Maria Teresa Bassi; Laura Obici; Eugenio A Parati; Alessando Pezzini; Maria Luisa De Lodovici; Elena P Verrengia; Giorgio Bono; Francesca Mazucchelli; Davide Zarcone; Maria Vittoria Calloni; Patrizia Perrone; Bianca Maria Bordo; Antonio Colombo; Alessandro Padovani; Anna Cavallini; Simone Beretta; Carlo Ferrarese; Cristina Motto; Elio Agostoni; Graziella Molini; Francesco Sasanelli; Manuel Corato; Simona Marcheselli; Maria Sessa; Giancarlo Comi; Nicoletta Checcarelli; Mario Guidotti; Davide Uccellini; Erminio Capitani; Lucia Tancredi; Marco Arnaboldi; Barbara Incorvaia; Carlo Sebastiano Tadeo; Laura Fusi; Giampiero Grampa; Giampaolo Merlini; Nadia Trobia; Giacomo Pietro Comi; Massimiliano Braga; Paolo Vitali; Pierluigi Baron; Caspar Grond-Ginsbach; Livia Candelise Journal: Stroke Date: 2016-05-31 Impact factor: 7.914
Authors: S Nakao; T Takenaka; M Maeda; C Kodama; A Tanaka; M Tahara; A Yoshida; M Kuriyama; H Hayashibe; H Sakuraba Journal: N Engl J Med Date: 1995-08-03 Impact factor: 91.245
Authors: C M Eng; J Fletcher; W R Wilcox; S Waldek; C R Scott; D O Sillence; F Breunig; J Charrow; D P Germain; K Nicholls; M Banikazemi Journal: J Inherit Metab Dis Date: 2007-03-08 Impact factor: 4.750
Authors: Alejandra Malavera; Dominique A Cadilhac; Vincent Thijs; Joyce Y Lim; Brenda Grabsch; Sibilah Breen; Stephen Jan; Craig S Anderson Journal: Front Neurol Date: 2020-11-24 Impact factor: 4.003